NanoViricides

NanoViricides, Inc. is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NanoViricides, Inc. is a clinical stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.

SHELTON, CT / ACCESSWIRE / February 15, 2022 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has filed the quarterly report for second quarter of its 2022 fiscal year with the Securities and Exchange Commission. This press release should be read in conjunction with the Company's Form 10-Q filed yesterday, February 14, 2022.

NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready

SHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), has filed its quarterly report for its first quarter of financial year 2022 with the Securities and Exchange Commission. This press release should be read in conjunction with the Company's Form 10-Q filed yesterday, on November 15, 2021.

NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials

NanoViricides, Inc. (NYSE: NNVC) announced Monday it has developed an oral gummies formulation of its COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients. The company believes the formulation may have advantages in terms of drug bioavailability over oral pills, because of partial sublingual absorption that avoids the gastrointestinal tract.

EXCLUSIVE: NanoViricides Completes Oral Gummies, Lung Inhalation Formulations For COVID-19 Treatment

SHELTON, CT / ACCESSWIRE / November 15, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, announced today that it has developed oral gummies formulations of its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients. Additionally, the Company has developed formulations for direct inhalation into lungs to benefit severely ill hospitalized patients.

NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2

SHELTON, CT / ACCESSWIRE / October 13, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2021 with the Securities and Exchange Commission (SEC) on Tuesday, October 12, 2021. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/0001379006/000110465921125343/tm2124471d1_10k.htm).

NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage

NanoViricides Inc. ( NNVC , Financial) is one of the emerging biotech companies that I have been following for a while now. Its stock price had more than doubled last month after a major update from the company with respect to the testing results of its drug candidate, which proved that it helped in enhancing the efficacy of Gilead's ( GILD , Financial) remdesivir for the treatment of Covid-19.

NanoViricides: There Is More to Come

Shares of NanoViricides Inc (NYSE: NNVC), a developer of antiviral therapies based on a novel nanomedicines technology, are higher Monday. What Happened: NanoViricides said its pan-Coronavirus COVID-19 drug candidate, NV-CoV-2, was found to be effective against SARS-CoV-2 in a standard cell culture pseudovirion assay.

NanoViricides COVID-19 Treatment Candidate Found Effective Against Coronavirus Variants In Lab Study

Shelton, Connecticut -- (October 11, 2021) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, announced today that its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 was found to be effective against SARS-CoV-2 in a standard cell culture pseudovirion assay, demonstrating that the drug indeed has broad-spectrum pan-coronavirus activity. This pan-coronavirus activity implies that the drug NV-CoV-2 should remain active in spite of evolution of variants of SARS-CoV-2 in the field, a highly sought-after characteristic to combat the current global pandemic.

NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity

SHELTON, CT / ACCESSWIRE / October 11, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, announced today that its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 was found to be effective against SARS-CoV-2 in a standard cell culture pseudovirion assay, demonstrating that the drug indeed has broad-spectrum pan-coronavirus activity. This pan-coronavirus activity implies that the drug NV-CoV-2 should remain active in spite of evolution of variants of SARS-CoV-2 in the field, a highly sought-after characteristic to combat the current global pandemic.

NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity.

Photo by Louis Reed on Unsplash Since the coronavirus pandemic started, scientists have worked to develop a vaccine to inoculate the population and stop the spread of COVID-19. The good news is they succeeded in producing multiple vaccines — in the U.S. Pfizer (NYSE: PFE), Johnson & Johnson (NYSE: JNJ), and Moderna (NASDAQ: MRNA) — that create antibodies to the SARS-CoV-2 in humans to prevent infection.

NanoViricides Leaps Forward in its Quest to Defeat COVID-19

There were a large number of pharma companies of all sizes that began their research on developing both drugs as well as vaccines to counter the SARS-CoV-2 since 2019. Some of these companies have succeeded and gained the limelight, while many others are still continuing their research in order to build more effective forms of medication.

NanoViricides: Why Has the Stock Doubled?

SHELTON, Conn., Sept. 22, 2021 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the significant advantages gained by remdesivir encapsulation within its lead COVID-19 candidate NV-CoV-2 thereby resulting in the dual-acting drug candidate NV-CoV-2-R with the promise of a potential pan-coronavirus cure.

Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug

A Covid-19 treatment producer halted trading this morning, but news has revealed that NNVC stock is still moving upward. The post NNVC Stock: What Is Going on With Red-Hot NanoViricides Today?

NNVC Stock: What Is Going on With Red-Hot NanoViricides Today?

Nanoviricides Inc. (NYSE:NNVC) shares are surging higher Tuesday following news of the company reporting significant advantages gained by remdesivir encapsulation within its lead COVID-19 candidate, thus showing a potential pan-coronavirus cure. Nanoviricides was up 55% to $5.79 at publication time.

Nanoviricides Stock Surges, Nears The End Of A Pennant Pattern

Today, NanoViricides is grabbing a lot of attention due to a news pending halt that has sent NNVC stock skyrocketing. The post What Is a ‘News Pending' Halt?

What Is a ‘News Pending' Halt? What to Know as NNVC Stock Captivates Investors

The stock price of NanoViricides Inc (NYSEAMERICAN: NNVC) increased by over 40% pre-market today. This is why it happened.

NNVC Stock: Why It Increased Today

SHELTON, Conn., Sept. 14, 2021 /PRNewswire/ -- NanoViricides, Inc. (NYSE Amer.

NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development

With the coronavirus changing the world in 2020, it makes sense that there's a spotlight on science to prevent viruses from growing into pandemics. While Pfizer (NYSE: PFE) and Moderna Inc. (NASDAQ: MRNA) worked on mRNA vaccines to quell the spread of COVID-19, NanoViricides Inc. (NYSE: NNVC) is taking a different approach.

NanoViricides Review: What you Need to Know About the Company

SHELTON, CT / ACCESSWIRE / May 17, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), has filed its quarterly report for its third quarter of financial year 2021 with the Securities and Exchange Commission. This press release should be read in conjunction with the Company's Form 10-Q filed on May 14, 2021.

NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards IND

SHELTON, CT / ACCESSWIRE /  March 9, 2021 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the strong effectiveness of its two COVID-19 clinical drug candidates in an animal model of coronavirus infection. The Company is preparing a pre-IND application encompassing its two clinical drug candidates for the treatment of COVID-19 infected patients.

NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in Support of FDA Pre-IND Application

The stock price of NanoViricides Inc (NYSEAMERICAN: NNVC) increased by 57.58%. This is why it happened.

NNVC Stock Price Increased 57.58%: Why It Happened

Shares of nano-cap biopharma NanoViricides, Inc. (NASDQ: NNVC) were trading solidly higher Tuesday following a positive data readout. What Happened: Two NanoViricides COVID-19 clinical drug candidates — NV-CoV-2 and NV-CoV-2-R — have shown "strong pan-coronavirus effectiveness" in preclinical studies, the company said.

NanoViricides Jumps On 'Strong Pan-Coronavirus Effectiveness' From 2 COVID-19 Candidates In Lab Studies

NanoViricides (NNVC) stock is on the rise Tuesday after revealing results from the company's drug candidates to treat the coronavirus. The post NNVC Stock: The COVID-19 Drug News That Has NanoViricides Rocketing Today appeared first on InvestorPlace.

NNVC Stock: The COVID-19 Drug News That Has NanoViricides Rocketing Today

The stock price of NanoViricides, Inc. (NYSEAMERICAN: NNVC) is trading at over 35% pre-market. This is why it happened.

NNVC Stock Price Increases Over 35% Pre-Market: Why It Happened

SHELTON, CT / ACCESSWIRE / March 2, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicine technology platform, reported today on the strong pan-coronavirus effectiveness of its two COVID-19 clinical drug candidates for which the Company is preparing a pre-IND application. NV-CoV-2 is the Company's broad-spectrum anti-coronavirus clinical lead drug candidate for the treatment of COVID-19 patients based on its nanoviricides® platform.

NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application

News for NanoViricides Stock (NNVC)